Article 57 product data

EMEA-003474-PIP01-23

EMEA-003482-PIP01-23

Opinion/decision on a Paediatric investigation plan (PIP): Tezspire, tezepelumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Gastroentology-Hepatology, PIP number: P/0407/2023

Leqembi recommended for treatment of early Alzheimer’s disease

EMEA-003442-PIP01-23

EMEA-002721-PIP04-23

Human medicines European public assessment report (EPAR): Leqembi, Lecanemab, Status: Opinion

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 11, Status: Authorised

Quality Review of Documents (QRD) working group plenary meeting dates